Initial work on utilising this knowledge for targeted gene therapy centred on the use of HCC restricted tumour specific promoters, such as that for alpha- fetoprotein (AFP), to drive transgene expression [41]. This evidence concerns the gene AFP and hepatocellular carcinoma.